The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors
Abstract
LY354740 is a conformationally constrained analog of glutamate which is a potent agonist for group II cAMP coupled metabotropic glutamate receptors (mGluRs). The discovery of this novel pharmacological agent has allowed the exploration of the functional consequences of activating group II mGluRs in vivo. In an effort to evaluate the clinical utility of LY354740 as an anxiolytic, we examined its effects in the fear potentiated startle and elevated plus maze models of anxiety and compared the results with the clinically prescribed anxiolytic diazepam. In the fear potentiated startle and elevated plus maze models, both LY354740 and diazepam produced significant anxiolytic activity (ED50 values of 0.3 and 0.4 mg/kg p. o. for fear potentiated startle and 0.2 and 0.5 mg/kg for the elevated plus maze, respectively). The duration of pharmacological effect for LY354740 in the efficacy models was 4 to 8 hr. In contrast to diazepam, acute administration of LY354740 did not produce sedation, cause deficits in neuromuscular coordination, interact with central nervous system depressants, produce memory impairment or change convulsive thresholds at doses 100- to 1000-fold the efficacious doses in animal models of anxiety. Thus, LY354740 has anxiolytic activity in animal models that are sensitive to benzodiazepines such as diazepam. However, at anxiolytic doses in these models, LY354740 produced none of the unwanted secondary pharmacology associated with diazepam. These data indicate a functional role for group II mGluRs in fear/anxiety responses in animals and suggest that compounds in this class may be beneficial in the treatment of anxiety-related disorders in humans without the side effects seen with currently prescribed medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
The use of a plus-maze to measure anxiety in the mouse
Lister, R. (1987) · Psychopharmacology · doi:10.1007/bf00177912 · Cited by 2,609
The metabotropic glutamate receptors: Structure and functions
Pin, J.-P., & Duvoisin, R. (1995) · Neuropharmacology · doi:10.1016/0028-3908(94)00129-g · Cited by 2,266
Psychopharmacology: The Third Generation of Progress.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-509_2 · Cited by 2,014
Miserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Metabotropic glutamate receptors in brain function and pathology
Schoepp, D. D., & Conn, P. J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90107-u · Cited by 791
Self-citationNeurotransmission in the rat amygdala related to fear and anxiety
Davis, M., Rainnie, D., & Cassell, M. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90106-6 · Cited by 771
A new type of glutamate receptor linked to inositol phospholipid metabolism
Sugiyama, H., Ito, I., & Hirono, C. (1987) · Nature · doi:10.1038/325531a0 · Cited by 762
Glutamate stimulates inositol phosphate formation in striatal neurones
Sladeczek, F., Pin, J.-P., Récasens, M., Bockaert, J., & Weiss, S. (1985) · Nature · doi:10.1038/317717a0 · Cited by 754
Fear-potentiated startle: A neural and pharmacological analysis
Davis, M., Falls, W. A., Campeau, S., & Kim, M. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90102-v · Cited by 748
DRUG INTERACTIONS AT THE GABA RECEPTOR-IONOPHORE COMPLEX
Olsen, R. W. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.001333 · Cited by 695
COMPARATIVE ASSAYS OF ANTIEPILEPTIC DRUGS IN MICE AND RATS
Swinyard, E. A., Brown, W. C., & Goodman, L. S. (1952) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)05100-6 · Cited by 633
Petralia, R. S., Wang, Y.-X., Niedzielski, A. S., & Wenthold, R. J. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00533-1 · Cited by 579
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Ohishi, H., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90485-x · Cited by 560
Use of the elevated plus maze in the search for novel anxiolytic agents
Dawson, G. R., & Tricklebank, M. D. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88973-7 · Cited by 559
Ohishi, H., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903350209 · Cited by 512
Campeau, S., & Davis, M. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-03-02301.1995 · Cited by 479
Nicoletti, F., Meek, J. L., Iadarola, M. J., Chuang, D. M., Roth, B. L., & Costa, E. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb12922.x · Cited by 464
Molecular Diversity and Functions of Glutamate Receptors
Nakanishi, S., & Masu, M. (1994) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.bb.23.060194.001535 · Cited by 446
The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety
Davis, M. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90014-w · Cited by 427
Monn, J. A., Valli, M. J., Massey, S. M., Wright, R. A., Salhoff, C. R., Johnson, B. G., Howe, T., Alt, C. A., Rhodes, G. A., Robey, R. L., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606756 · Cited by 390
Self-citationDavis, M. (1986) · Behavioral Neuroscience · doi:10.1037//0735-7044.100.6.814 · Cited by 343
Abuse liability of benzodiazepines.
Woods, J. H., Katz, J. L., & Winger, G. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06658-x · Cited by 315
Pharmacology and neurochemistry of buspirone.
Riblet, L. A., Taylor, D. P., Eison, M. S., & Stanton, H. C. (1982) · PubMed · Cited by 287
Inhibitory transmission in the basolateral amygdala
Rainnie, D. G., Asprodini, E. K., & Shinnick-Gallagher, P. (1991) · Journal of Neurophysiology · doi:10.1152/jn.1991.66.3.999 · Cited by 279
Davis, M. (1979) · Psychopharmacology · doi:10.1007/bf00426027 · Cited by 263
Dependence, Tolerance, and Addiction to Benzodiazepines: Clinical and Pharmacokinetic Considerations
Greenblatt, D. J., & Shader, R. I. (1978) · Drug Metabolism Reviews · doi:10.3109/03602537808993775 · Cited by 229
SCHOEPP, D. D., JOHNSON, B. G., WRIGHT, R. A., SALHOFF, C. R., MAYNE, N. G., WU, S., COCKERHAM, S. L., PAUL BURNETT, J., BELEGAJE, R., BLEAKMAN, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225
Self-citationSchoepp, D. D., & Johnson, B. G. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb03050.x · Cited by 178
Self-citationBehavioral effects of benzodiazepines: A review
Dantzer, R. (1977) · Biobehavioral Reviews · doi:10.1016/0147-7552(77)90014-6 · Cited by 171
Kim, M., Campeau, S., Falls, W. A., & Davis, M. (1993) · Behavioral and Neural Biology · doi:10.1016/0163-1047(93)91075-x · Cited by 164
Excitatory transmission in the basolateral amygdala
Rainnie, D. G., Asprodini, E. K., & Shinnick-Gallagher, P. (1991) · Journal of Neurophysiology · doi:10.1152/jn.1991.66.3.986 · Cited by 164
Novel functions for subtypes of metabotropic glutamate receptors.
Schoepp, D. (1994) · Neurochemistry International · doi:10.1016/0197-0186(94)90092-2 · Cited by 136
Self-citationWiley, J. L., Cristello, A. F., & Balster, R. L. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00506-4 · Cited by 121
Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm
Kehne, J. H., Cassella, J. V., & Davis, M. (1988) · Psychopharmacology · doi:10.1007/bf00735872 · Cited by 93
Anxiolytic-like effects of glycine receptor ligands in the rat potentiated startle test
Anthony, E. W., & Nevins, M. E. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90397-z · Cited by 86
Rainnie, D. G., & Shinnick‐Gallagher, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90864-4 · Cited by 81
5-HT1A Agonists, 5-HT3 Antagonists and Benzodiazepines: Their Comparative Behavioral Pharmacology.
Bakish, D., & Hooper, C. L. (1994) · Europe PMC (PubMed Central) · Cited by 36
Central nervous system characterization of the new cholecystokininB antagonist LY288513
Helton, D. R., Berger, J. E., Czachura, J. F., Rasmussen, K., & Kallman, M. J. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02122-1 · Cited by 29
Self-citation
Cited by
Glutamate as a neurotransmitter in the brain: review of physiology and pathology
Meldrum, B. S. (2000) · The Journal of Nutrition · doi:10.1093/jn/130.4.1007s · Cited by 1,667
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Self-citationReversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Glutamate receptor function in learning and memory
Riedel, G. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00272-3 · Cited by 962
Metadata
- Authors
- Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1998-02
- Volume
- 284
- Issue
- 2
- Pages
- 651-660
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2167891371
- Cited by
- 279
- References
- 40
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.